FFC#4/2022

Esculentin-derived peptides as novel therapeutic agents with antimicrobial and CFTR potentiator activities to address cystic fibrosis lung disease

AREA 1 Therapies to correct the underlying defect

FFC#4/2022

Esculentin-derived peptides as novel therapeutic agents with antimicrobial and CFTR potentiator activities to address cystic fibrosis lung disease
€ 0 still needed
0%
€ 130.000 goal

Partner

Arianna Venturini (TIGEM, Pozzuoli), Mattia Mori (Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Italy)

Researchers

13

Category

AREA 1 Therapies to correct the underlying defect

Duration

2 years

Goal

€ 130.000

Funds raised

€ 130.000

Objectives

Researchers have identified through previous projects (FFC#14/2011FFC#11/2014FFC#15/2017 and FFC#8/2019) antimicrobial peptides (AMPs) derived from the natural compound Esculentin that have shown high efficacy against Pseudomonas aeruginosa. The research team also recently discovered that these Esc peptides are able to act as potentiators of the F508del mutated CFTR channel. The project aims to study the effect of Esc peptides as potentiators of mutated CFTR modulators by evaluating their possible additive/ synergistic effects. In addition, the research group aims to optimize the efficacy of peptides for their dual antimicrobial and potentiating function. A further aim of the project is to evaluate the ability of the selected peptides to preserve the antibacterial activity in the lung through a multidisciplinary approach both in vitro and in vivo.

CHI HA ADOTTATO IL PROGETTO

Delegazione FFC Ricerca di Roma

€ 65.000

Delegazione FFC Ricerca della Franciacorta e Val Camonica

€ 65.000

Delegazione FFC Ricerca di Catania Paternò

€ 30.000

OTHER PROJECTS

Discover the other projects

GMRF#1/2026

Exploring the role of PKD1 in promoting CFTR stability and function at the cell surface

FFC#1/2026

Mapping proteins regulating CFTR mRNA stability to identify new therapeutic targets for nonsense mutations

FFC#2/2026

Evaluating the potential of phosphodiesterase inhibitors to enhance the efficacy of CFTR modulators and support personalized therapeutic approaches